| pubmed-article:20705965 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20705965 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20705965 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:20705965 | lifeskim:mentions | umls-concept:C0086445 | lld:lifeskim |
| pubmed-article:20705965 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20705965 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:20705965 | pubmed:dateCreated | 2010-12-8 | lld:pubmed |
| pubmed-article:20705965 | pubmed:abstractText | It was postulated that in patients with membranous nephropathy (MN), four weekly doses of Rituximab (RTX) would result in more effective B cell depletion, a higher remission rate, and maintaining the same safety profile compared with patients treated with RTX dosed at 1 g every 2 weeks. This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment. | lld:pubmed |
| pubmed-article:20705965 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20705965 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20705965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20705965 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20705965 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:20705965 | pubmed:issn | 1555-905X | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:RosenblatMM | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:CattranDaniel... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:SpecksUlrichU | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:NachmanPatric... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:AbrahamRoshin... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:HoganMarie... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:BergstralhEri... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:LeungNelsonN | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:FervenzaFerna... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:CosioFernando... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:EricksonSteph... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:LiXujianX | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:HicksonLaTony... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:IrazabalMaria... | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:EirinAlfonsoA | lld:pubmed |
| pubmed-article:20705965 | pubmed:author | pubmed-author:Mayo... | lld:pubmed |
| pubmed-article:20705965 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20705965 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:20705965 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20705965 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20705965 | pubmed:pagination | 2188-98 | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:meshHeading | pubmed-meshheading:20705965... | lld:pubmed |
| pubmed-article:20705965 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20705965 | pubmed:articleTitle | Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. | lld:pubmed |
| pubmed-article:20705965 | pubmed:affiliation | Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55901, USA. fervenza.fernando@mayo.edu | lld:pubmed |
| pubmed-article:20705965 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20705965 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20705965 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
